Minnetronix Medical and INO Announce Strategic Partnership that Fast Tracks Optical Medical Device Development & Commercialization

Cutting-Edge Applied Research and Technology Save Time and Money throughout the Product Lifecycle

Minnetronix Medical, a U.S.-based medical device technology partner offering full lifecycle design and manufacturing services, and INO Innovation Center, Canada’s largest and most advanced center of applied research and expertise in optics and photonics, have announced a strategic partnership to innovate and accelerate bringing optical medical devices to market.

Working with the Minnetronix-INO team, medical device companies gain access to deep expertise in optics and photonics and a seamless solution for bringing highly integrated optical medical devices from concept through commercial production.

Minnetronix’ suite of services is unique in the medical device industry because it includes full lifecycle support across medical device design, development, supply chain, and manufacturing. INO is a global leader in the optics field with the ability to control light to capture, identify, predict, and transform data into valuable and actionable information through multiple light applications — from laser and fiber optic technologies to imaging systems.

“There is increased complexity in creating optical medical devices, which this partnership solves,” said Matt Adams, vice president and general manager at Minnetronix. “For example, the supply chain for complex medical optics is often fragmented requiring customers to find specialized expertise in multiple small firms. Now, customers get the best brains in the industry under one umbrella to get their products to market faster.” Adams adds that combining this joint expertise with a simple onboarding and project management process allows customers to seamlessly engage the team as a “one-stop shop” for optic and photonic projects.

“With more than 50 years of leading expertise in optics between INO and Minnetronix, our combined strengths will play a significant role in advancing our customers’ optics-based medical devices to the market.” said Louis Martel, Vice President Business Development and Partnership at INO.

The new partnership expands Minnetronix’ optics business and INO’s reach into the U.S. INO has implemented more than 6,500 solutions, carried out 75 technology transfers, and contributed to the creation of 35 new companies.

The new collaboration has already completed its first successful project: INO developed a smart illumination system when no other commercial solutions were available, while Minnetronix led the complex system integration, including the proprietary illumination system, to deliver the final product to the customer.

The partnership can also manage projects that require optical subsystems within larger, complex medical device systems; have complicated or diverse supply chains and/or require regulatory insights to scope design considerations relative to the FDA pathway.

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modificatio. Analysis of 72 patients treated in STK-001 clinical trials suggests that higher STK-001 drug exposure in brain leads to greater seizure reductions. Two-year data from the longest prospective natural history study of Dravet syndrome showed that, on average, patients experienced no meaningful improvement in convulsive seizure frequency and exhibited widening gaps in cognition and behavior despite treatment with the best available anti-seizure medicines.
"Exact Sciences is looking forward to presenting new evidence at SABCS that adds important perspectives to treating breast cancer patients and showing that some patients may be able to de-escalate treatments and still have positive outcomes," said Dr. Rick Baehner, Chief Medical Officer, Precision Oncology, Exact Sciences. "Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients. We are pleased to see authorities expanding access to this test as we continue to develop key evidence in collaboration with some of the world's most prestigious, breast cancer-focused organizations."
Clozapine has been established as the most effective antipsychotic medication for treatment-resistant schizophrenia. However, it is significantly underutilized mainly due to the risk of developing agranulocytosis and the need to frequently monitor the absolute neutrophil count (ANC).
Dagi-Ben Noon, CEO of Inspira Technologies, reflects on the partnership's significance: "By Integrating our technology to oxygenate blood directly with Ennocure's infection prevention solutions, we are focusing on potentially improving patient outcomes in ICUs and paving the way for safer, more effective life-support treatments. This collaboration is expected to accelerate the development and broaden the implementation of our advanced technology."
The findings suggest that the novel, non-invasive genomic test can help physicians guide next steps for these patients, enabling them to potentially avoid unnecessary invasive procedures or accelerate time to appropriate treatment.

By using this website you agree to accept Medical Device News Magazine Privacy Policy